{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=8", "query": { "intervention": "Doxorubicin Hydrochloride (DOX)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1374, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+Hydrochloride+%28DOX%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:04:31.794Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03646188", "title": "Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Placebo-containing MNA", "type": "DRUG" }, { "name": "25 µg doxorubicin-containing MNA", "type": "DRUG" }, { "name": "50 µg doxorubicin-containing MNA", "type": "DRUG" }, { "name": "100 µg doxorubicin-containing MNA", "type": "DRUG" }, { "name": "200 µg doxorubicin-containing MNA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SkinJect, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 13, "start_date": "2020-06-10", "completion_date": "2021-05-04", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 1, "location_summary": "Aventura, Florida", "locations": [ { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646188" }, { "nct_id": "NCT02082886", "title": "HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Peritoneal Neoplasms", "Neoplasm Metastasis", "Adenocarcinoma", "Sarcoma" ], "interventions": [], "intervention_types": [], "sponsor": "Edward-Elmhurst Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 193, "start_date": "2014-02", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 2, "location_summary": "Elmhurst, Illinois • Naperville, Illinois", "locations": [ { "city": "Elmhurst", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082886" }, { "nct_id": "NCT01042041", "title": "Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Liver Cancer", "Localized Unresectable Liver Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "transarterial chemoembolization", "type": "PROCEDURE" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2013-02-26", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042041" }, { "nct_id": "NCT00352027", "title": "Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma" ], "interventions": [ { "name": "Adriamycin®", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Nitrogen Mustard", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Radiotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 81, "start_date": "2006-07-20", "completion_date": "2022-11-15", "has_results": true, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 6, "location_summary": "Palo Alto, California • San Diego, California • Portland, Maine + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Portland", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352027" }, { "nct_id": "NCT06630091", "title": "A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Golidocitinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-02-21", "completion_date": "2029-07-05", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630091" }, { "nct_id": "NCT01902225", "title": "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "T-Cell Lymphoma", "Cutaneous Lymphoma" ], "interventions": [ { "name": "Istodax", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weiyun Ai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2014-03-04", "completion_date": "2020-04-11", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 2, "location_summary": "San Francisco, California • Columbus, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01902225" }, { "nct_id": "NCT00283621", "title": "Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Aranesp (darbepoetin alfa)", "type": "DRUG" }, { "name": "Neulasta (pegfilgrastim)", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2003-06-02", "completion_date": "2006-04-12", "has_results": false, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283621" }, { "nct_id": "NCT01990352", "title": "Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-11-05", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 2, "location_summary": "Tucson, Arizona • Albuquerque, New Mexico", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT01990352" }, { "nct_id": "NCT00001384", "title": "A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "Adriamycin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1994-05", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001384" }, { "nct_id": "NCT02783599", "title": "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Olaratumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "External Beam Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-10-11", "completion_date": "2018-07-05", "has_results": true, "last_update_posted_date": "2019-08-12", "last_synced_at": "2026-10-15T00:04:31.794Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • St. Petersburg, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783599" } ] }